Literature DB >> 35723810

Silencing CircEIF3I/miR-526b-5p Axis Epigenetically Targets HGF/c-Met Signal to Hinder the Malignant Growth, Metastasis and Angiogenesis of Hepatocellular Carcinoma.

Yang Liu1, Xia Xiao2, Jingying Wang3, Yitong Wang2, Yanhui Yu4.   

Abstract

BACKGROUND: Hepatocyte growth factor (HGF)/c-mesenchymal-epithelial transition factor (c-Met) is important for the diagnosis and prognosis of hepatocellular carcinoma (HCC). Circular RNAs (circRNAs) are key regulators of HCC progression, and this study focused on circRNA eukaryotic translation initiation factor 3 subunit I (circEIF3I) with HGF/c-Met in HCC.
METHODS: Levels of circEIF3I, microRNA (miR)-526b-5p, HGF, E-cadherin, N-cadherin, and Vimentin were detected by Gene Expression Omnibus database, quantitative PCR and western blotting. Cell functions were measured by detecting cell growth (cell proliferation assay with WST-1 and EdU, colony formation assay, flow cytometry, caspase 3 activity assay, and nude mouse tumorigenicity assay), metastasis (transwell assay and western blotting), angiogenesis (endothelial tube formation assay). Molecular interaction was determined dual-luciferase reporter assay, RNA immunoprecipitation, and Pearson correlation analysis.
RESULTS: Expression of circEIF3I was upregulated in HCC tissues. Knockdown of circEIF3I suppressed cell proliferation epithelial-mesenchymal transition, migration, invasion and tube formation ability but promoted apoptosis of HCC cells. CircEIF3I could sponge miR-526b-5pto regulate downstream HGF. Functionally, circEIF3I regulation in HCC cell progression was associated with miR-526b-5p sponging function and HGF upregulation could attenuate tumor-inhibiting roles of miR-526b-5p. HCC tumor growth was delayed by interfering circEIF3I.
CONCLUSION: CircEIF3I was an oncogenic circRNA in HCC-, and interfering circEIF3I exhibited anti-HCC activity via circEIF3I-miR-526b-5p-HGF/c-Met pathway.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  HCC; HGF; circEIF3I; miR-526b-5p

Year:  2022        PMID: 35723810     DOI: 10.1007/s10528-022-10239-y

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   1.890


  57 in total

Review 1.  miRNA sponges: soaking up miRNAs for regulation of gene expression.

Authors:  Rasmus O Bak; Jacob Giehm Mikkelsen
Journal:  Wiley Interdiscip Rev RNA       Date:  2013-12-23       Impact factor: 9.957

Review 2.  Role of renin-angiotensin system in liver diseases: an outline on the potential therapeutic points of intervention.

Authors:  Elham Ahmadian; Peter S Pennefather; Aziz Eftekhari; Reza Heidari; Mohammad Ali Eghbal
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2016-07-14       Impact factor: 3.869

Review 3.  Tivantinib for the treatment of hepatocellular carcinoma.

Authors:  Jan Best; Clemens Schotten; Gregor Lohmann; Guido Gerken; Alexander Dechêne
Journal:  Expert Opin Pharmacother       Date:  2017-04-17       Impact factor: 3.889

Review 4.  Live to die another way: modes of programmed cell death and the signals emanating from dying cells.

Authors:  Yaron Fuchs; Hermann Steller
Journal:  Nat Rev Mol Cell Biol       Date:  2015-05-20       Impact factor: 94.444

5.  MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2.

Authors:  Alip Ghosh; Debanjali Dasgupta; Amit Ghosh; Shrabasti Roychoudhury; Dhiraj Kumar; Mahadeo Gorain; Ramesh Butti; Simanti Datta; Shaleen Agarwal; Subash Gupta; Gopal Krishna Dhali; Abhijit Chowdhury; Thomas D Schmittgen; Gopal C Kundu; Soma Banerjee
Journal:  Cell Death Dis       Date:  2017-03-30       Impact factor: 8.469

Review 6.  Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications.

Authors:  Javier A García-Vilas; Miguel Ángel Medina
Journal:  World J Gastroenterol       Date:  2018-09-07       Impact factor: 5.742

7.  CircularRNA circ_0071269 knockdown protects against from diabetic cardiomyopathy injury by microRNA-145/gasdermin A axis.

Authors:  Lanfang Fu; Juyun Zhang; Zhu Lin; Yi Li; Guijun Qin
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

8.  The has-miR-526b binding-site rs8506G>a polymorphism in the lincRNA-NR_024015 exon identified by GWASs predispose to non-cardia gastric cancer risk.

Authors:  Qiu-Hong Fan; Rong Yu; Wei-Xian Huang; Xi-Xi Cui; Bing-Hui Luo; Li-Yuan Zhang
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.752

Review 9.  Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.

Authors:  Mohamed Bouattour; Eric Raymond; Shukui Qin; Ann-Lii Cheng; Uz Stammberger; Giuseppe Locatelli; Sandrine Faivre
Journal:  Hepatology       Date:  2018-02-01       Impact factor: 17.425

10.  c-Met enforces proinflammatory and migratory features of human activated CD4+ T cells.

Authors:  Mahdia Benkhoucha; Ngoc Lan Tran; Gautier Breville; Isis Senoner; Camilla Jandus; Patrice Lalive
Journal:  Cell Mol Immunol       Date:  2021-06-28       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.